ORKA (Oruka Therapeutics) Tariff Resilience Score: 6/10 (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORKA Oruka Therapeutics Inc ORKA
14 GF Score
Price $92.15
! 3 Warning Signs
View Full Analysis

What is Oruka Therapeutics Tariff Resilience Score?

Oruka Therapeutics ORKA +0.29% 14 Tariff Resilience Score is 6 as of Jul. 27, 2026. GuruFocus rates ORKA with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,367 Biotechnology companies, Oruka Therapeutics ranks better than 76.01% on this metric.

Oruka Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Oruka Therapeutics has Oruka Therapeutics has a moderate exposure to tariffs due to its reliance on international raw materials. However, its niche pharmaceutical products have some pricing power, and the company is exploring alternative suppliers to mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Oruka Therapeutics might have Average Resilient.

Oruka Therapeutics  (NAS:ORKA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Oruka Therapeutics Tariff Resilience Score Related Terms

ORKA vs DNTH, SRRK, DFTX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Oruka Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Tariff Resilience Score falls into.


ORKA
14GF Score
Oruka Therapeutics Inc ORKA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Oruka Therapeutics (ORKA) has a Tariff Resilience Score of 6 as of Jul. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Oruka Therapeutics ranks #328 out of 1367 companies in the Biotechnology industry, placing it in the top 24%.
Is Oruka Therapeutics' Tariff Resilience Score too high?
Oruka Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Oruka Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Oruka Therapeutics ranks #328 out of 1367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oruka Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Oruka Therapeutics' Tariff Resilience Score compare to DNTH and SRRK?
According to the Biotechnology industry distribution chart, Oruka Therapeutics ranks #328 out of 1367 companies for Tariff Resilience Score. This places Oruka Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Oruka Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oruka Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oruka Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oruka Therapeutics stock overvalued right now?
Oruka Therapeutics (ORKA) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Oruka Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Oruka Therapeutics (ORKA), the current Tariff Resilience Score is 6 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oruka Therapeutics Business Description

Other Exchanges HQ1:Germany
Address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
14GF Score

Get the complete analysis for ORKA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$92.15
Price